GO CAPITAL invested in Alkion BioInnovations' EUR4.4M raise to industrialize sustainable production of QS-21 vaccine adjuvants.
Alkion BioInnovations is pioneering the next-gen active ingredient bioproduction platform for the development and large-scale supply of critical vaccines and treatments, focusing on sustainable plant tissue technologies
Alkion BioInnovations is pioneering the next-gen active ingredient bioproduction platform for the development and large-scale supply of critical vaccines and treatments, focusing on sustainable plant tissue technologies.